Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
1983 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 12 Suppl A, 283-7 p.Article in journal (Refereed) Published
Ceftazidime (50 mg/kg/8 h) alone or combined with tobramycin (5 mg/kg/8 h) was given to 14 patients with cystic fibrosis. Ten courses were given with ceftazidime alone and 6 courses with a combined therapy. All patients were chronically colonized with Pseudomonas aeruginosa and were hospitalized because of lower respiratory tract infections. Using an agar-well diffusion technique, the concentration of ceftazidime was determined in serum and sputum. The mean (+/- S.E.M.) peak serum concentration of ceftazidime was 142 +/- 16 mg/l during the second to third day of treatment and 114 +/- 18 mg/l on the fifth to sixth day of treatment. In the combined therapy the corresponding values were 104 +/- 20 mg/l and 74 +/- 8 mg/l, respectively. The range of the mean half life was 1.2 to 1.4 h. The maximum concentration of ceftazidime in sputum was usually obtained 1 h after the infusion, ranging from 0.7 to 9.8 mg/l. All patients improved during treatment. Non-mucoid strains of Ps. aeruginosa were eradicated in nearly half of the courses, mucoid strains less often. No side reactions were noted.
Place, publisher, year, edition, pages
1983. Vol. 12 Suppl A, 283-7 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:umu:diva-35362PubMedID: 6352633OAI: oai:DiVA.org:umu-35362DiVA: diva2:343472